From Diligence To Execution — Tim Wright's Approach To Leading MiMedx
Source: Life Science Leader
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
“The Bad News Keeps Coming For MiMedx And Its New Auditor EY,” read the July 3, 2018, MarketWatch headline.
The publicly traded biopharma faced an accounting scandal involving three former executives (i.e., CEO, COO, and CFO), and consequently, would have to restate more than five years of financials. And more trouble would soon follow. It makes you wonder what type of person would want to take on leading a company that was facing such significant reputational challenges. How about 36-year biopharma veteran Tim Wright?
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up
Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more